FILE - In this Monday, Feb. 6, 2012, file photo, Alexis McKenzie, right, executive director of The Methodist Home of the District of Columbia Forest Side, an Alzheimer's assisted-living facility, puts her hand on the arm of a resident in Washington. Combined results released Monday, Oct. 8, 2012, from two studies of an experimental Alzheimer's drug called solanezumab, under development by Eli Lilly & Co., suggest that it might modestly slow mental decline, especially in patients with mild disease. (AP Photo/Charles Dharapak, File)

Associated Press
FILE - In this Monday, Feb. 6, 2012, file photo, Alexis McKenzie, right, executive director of The Methodist Home of the District of Columbia Forest Side, an Alzheimer's assisted-living facility, puts her hand on the arm of a resident in Washington. Combined results released Monday, Oct. 8, 2012, from two studies of an experimental Alzheimer's drug called solanezumab, under development by Eli Lilly & Co., suggest that it might modestly slow mental decline, especially in patients with mild disease. (AP Photo/Charles Dharapak, File)
FILE - In this Monday, Feb. 6, 2012, file photo, Alexis McKenzie, right, executive director of The Methodist Home of the District of Columbia Forest Side, an Alzheimer's assisted-living facility, puts her hand on the arm of a resident in Washington. Combined results released Monday, Oct. 8, 2012, from two studies of an experimental Alzheimer's drug called solanezumab, under development by Eli Lilly & Co., suggest that it might modestly slow mental decline, especially in patients with mild disease. (AP Photo/Charles Dharapak, File)
View Comments (0)